Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will help to execute on advancing company's key clinical and commercial initiatives, including the resubmission of its NDA for FDA approval of lead product Libervant™ Buccal Film and ongoing clinical trial for AQST-108.
Lead Product(s): Diazepam
Therapeutic Area: Neurology Product Name: Libervant
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Aquestive Therapeutics
Deal Size: $85.0 million Upfront Cash: Undisclosed
Deal Type: Agreement November 23, 2020